Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: Results of the GO-MORE study

Annals of the Rheumatic Diseases

Volumn 73, Issue 8, 2014, Pages 1477-1486

  Combe, Bernard ^a   Dasgupta, Bhaskar ^b   Louw, Ingrid ^c   Pal, Sarvajeet ^d   Wollenhaupt, Jürgen ^e   Zerbini, Cristiano A F ^f   Beaulieu, Andre D ^g   Schulze Koops, Hendrik ^h   Durez, Patrick ⁱ   Yao, Ruji ^j   Vastesaeger, Nathan ^k   Weng, Haoling H ^j  

^a LAPEYRONIE HOSPITAL   (France)

^b SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^c Panorama Medi Clinic   (South Africa)

^d Advance Rheumatology Clinic   (India)

^e Schon Klinik Hamburg Eilbek   (Germany)

^f HOSPITAL HELIÓPOLIS   (Brazil)

^g Centre de Rhumatologie   (Canada)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j MERCK RESEARCH LABORATORIES   (United States)

^k Merck Sharp and Dohme   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; GOLIMUMAB; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADD ON THERAPY; ADULT; ANEMIA; ARTICLE; BACTERIAL ARTHRITIS; BRONCHITIS; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY SCORE; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART FAILURE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; PANCREAS CARCINOMA; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SEPTIC SHOCK; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT RESPONSE; TUBERCULOSIS; URINARY TRACT INFECTION; UTERINE CERVIX CARCINOMA;

DMARDS (BIOLOGIC); METHOTREXATE; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903899526     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203229     Document Type: Article

References (26)

1. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
2. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45. (Pubitemid 46044858)
4. Smolen JS, Aletaha D, Bijlsma JW, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
5. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human antitumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83.
6. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
7. Smolen JS, Kay J, Doyle MK, et al.; GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.
8. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917-28.
9. Tanaka Y, Harigai M, Takeuchi T, et al.; GO-FORTH Study Group. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 2012;71:817-24.
10. Taylor PC, Ritchlin C, Mendelsohn A, et al. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. J Rheumatol 2011;38:2572-80.
11. Weinblatt ME, Bingham CO III, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3 randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013;72: 381-9.
12. Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis. Arthritis Rheum 2011;63:1200-10.
13. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9. (Pubitemid 38942816)
14. Zhou H, Jang H, Fleischmann R, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383-96. (Pubitemid 46294717)
15. Xu Z, Wang Q, Zhuang Y, et al. Subcutaneous bioavailability of golimumab at different injection sites in healthy subjects. J Clin Pharmacol 2010;50: 276-84.
16. Zhuang Y, Xu Z, Frederick B, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther 2012;34:77-90.
17. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36. (Pubitemid 41369090)
18. Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42.
19. Hyrich KL, Watson KD, Lunt M, et al. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 2011;50:117-23.
20. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007;34:1670-3. (Pubitemid 47267608)
21. De Punder YM, Fransen J, Kievit W, et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) 2012;51:1610-7.
22. Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66:732-9. (Pubitemid 46846691)
23. Weinblatt ME, Fleischmann R, Huizinga TWJ, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford) 2012;51:2204-14.
24. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis: a systematic review. J Rheumatol 2010;37:1096-104.
25. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898-908.
26. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.